참고문헌
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
- Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol 2016;22:2403-2414. https://doi.org/10.3748/wjg.v22.i8.2403
- Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 2008;14:1149-1155. https://doi.org/10.3748/wjg.14.1149
- Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011;2:77-84.
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
- Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909. https://doi.org/10.1200/JCO.2005.05.0245
- Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221. https://doi.org/10.1016/S1470-2045(08)70035-4
- Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 2015;26:141-148. https://doi.org/10.1093/annonc/mdu472
- Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442. https://doi.org/10.1200/JCO.2007.13.9378
- Mohri Y, Tanaka K, Toiyama Y, et al. Impact of preoperative neutrophil to lymphocyte ratio and postoperative infectious complications on survival after curative gastrectomy for gastric cancer: a single institutional cohort study. Medicine (Baltimore) 2016;95:e3125. https://doi.org/10.1097/MD.0000000000003125
- Li QQ, Lu ZH, Yang L, et al. Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev 2014;15:945-950. https://doi.org/10.7314/APJCP.2014.15.2.945
- Cho IR, Park JC, Park CH, et al. Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 2014;17:703-710. https://doi.org/10.1007/s10120-013-0330-2
- Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer 2012;107:275-279. https://doi.org/10.1038/bjc.2012.262
- Hsieh MC, Wang SH, Chuah SK, Lin YH, Lan J, Rau KM. A prognostic model using inflammation- and nutrition-based scores in patients with metastatic gastric adenocarcinoma treated with chemotherapy. Medicine (Baltimore) 2016;95:e3504. https://doi.org/10.1097/MD.0000000000003504
- Hsu JT, Liao CK, Le PH, et al. Prognostic value of the preoperative neutrophil to lymphocyte ratio in resectable gastric cancer. Medicine (Baltimore) 2015;94:e1589. https://doi.org/10.1097/MD.0000000000001589
- Yu L, Lv CY, Yuan AH, Chen W, Wu AW. Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer. World J Gastroenterol 2015;21:6280-6286. https://doi.org/10.3748/wjg.v21.i20.6280
- Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study. Korean J Intern Med 2016;31:891-898. https://doi.org/10.3904/kjim.2015.084
- Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899. https://doi.org/10.1016/j.cell.2010.01.025
- Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867. https://doi.org/10.1038/nature01322
- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. https://doi.org/10.1016/S0140-6736(00)04046-0
- Kishiki T, Masaki T, Matsuoka H, et al. Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg 2013;206:234-240. https://doi.org/10.1016/j.amjsurg.2012.07.051
- Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009;45:261-267. https://doi.org/10.1016/j.ejca.2008.10.028
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674. https://doi.org/10.1016/j.cell.2011.02.013
- Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 2013;73:4965-4977. https://doi.org/10.1158/0008-5472.CAN-13-0661
- Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 2013;23:141-148. https://doi.org/10.1016/j.semcancer.2013.02.005
- Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
- Im SA, Lee KE, Nam E, et al. The prognostic significance of the overexpression of HER-2/neu in Korean gastric carcinomas and the in vitro effects of anti-HER-2/neu antibody on cell growth in the gastric carcinoma cell lines. Cancer Res Treat 2003;35:109-116. https://doi.org/10.4143/crt.2003.35.2.109
- Song Y, Huang J, Wang JW. Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma. Chin J Cancer 2010;29:76-81. https://doi.org/10.5732/cjc.009.10412
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-1030. https://doi.org/10.1038/sj.bjc.6601242
- Choi WJ, Kim J. Nutritional care of gastric cancer patients with clinical outcomes and complications: a review. Clin Nutr Res 2016;5:65-78. https://doi.org/10.7762/cnr.2016.5.2.65
- Tan CS, Read JA, Phan VH, Beale PJ, Peat JK, Clarke SJ. The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer 2015;23:385-391. https://doi.org/10.1007/s00520-014-2385-y
- Dutta S, Al-Mrabt NM, Fullarton GM, Horgan PG, Mc-Millan DC. A comparison of POSSUM and GPS models in the prediction of post-operative outcome in patients undergoing oesophago-gastric cancer resection. Ann Surg Oncol 2011;18:2808-2817. https://doi.org/10.1245/s10434-011-1676-5
- Walsh SM, Casey S, Kennedy R, Ravi N, Reynolds JV. Does the modified Glasgow prognostic score (mGPS) have a prognostic role in esophageal cancer? J Surg Oncol 2016;113:732-737. https://doi.org/10.1002/jso.24225
- Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-4506. https://doi.org/10.4049/jimmunol.0802740
- Ohki S, Shibata M, Gonda K, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep 2012;28:453-458. https://doi.org/10.3892/or.2012.1812
피인용 문헌
- The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities vol.19, pp.None, 2018, https://doi.org/10.1186/s12885-019-5511-x
- Evaluation and validation of the prognostic value of nutrition and immunity parameters in gastric cancer after R0 resection vol.99, pp.8, 2018, https://doi.org/10.1097/md.0000000000019270
- Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients vol.10, pp.5, 2018, https://doi.org/10.3390/jcm10051079
- Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy vol.13, pp.13, 2018, https://doi.org/10.18632/aging.203256